Zealand Pharma — August 2022
-
Jeg fik skrevet "ingen omsætningen" , hvilket var bunden er det mulige interval. Der kommer meget små indtægter og omkostninger omkring 550 mio. kr. og der burde ikke komme nogle overraskelser med regnskabet, som ledelsen ikke allerede har udmeldt. Selskabet drives af forventningen til kommende 2 fase 3 resultater i H2 og nogle mulige milestones. Som et "normalt" bio-selskab, forventes dagens regnskab ikke, at være en "breaker" på det regnskabstekniske
-
og det er umiddelbart for tidligt, at se hvordan cash burn udviklinger sig efter omlægning af strategien.
-
Nydelig og fortjent cadeau til dig @exitnu
-
så eng mht @exitnu
-
@fandel køber?! Så skal jeg
ud:) spøg til side, velkommen i ZP-Klubben -
godt @YPE ! - er lige kommet hjem fra 38g i Rom - men aktierne er sgu dejligt varmere
-
-
vi er klar, Houston
-
Zealand Pharma Announces Financial Results for the First Half of 2022
"Net operating expenses in 2022 are expected to be DKK 1,000 million +/-10%. This is unchanged from our updated guidance issued on March 30, 2022 and is a decrease of DKK 200 million from the guidance issued on March 10, 2022."
-
ude nu
-
Zealand Pharma Announces Financial Results for the First Half of 2022
Company Announcement No. 34 / 2022 Interim report for H1 2022 Zealand Pharma Announces Financial Results for the First Half of 2022 Copenhagen, DK...
GlobeNewswire News Room (www.globenewswire.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind